Comparing the effects of Conbercept and Ranibizumab on proliferation and migration in RF/6A cells / 基础医学与临床

ABSTRACT

Objective To conduct a comparative research on the differences and mechanisms of the effects of Con-bercept and Ranibizumab on Rhesus choroidoretinal endothelial cells ( RF/6A cells) proliferation, migration effects induced by VEGF.Methods RF/6A cells were divided into six groups, namely control group, VEGF group, Con-bercept group , Ranibizumab group , Conbercept +VEGF group and Ranibizumab +VEGF group .CCK-8 assay , Transwell chambers , Annexin V-FITC/PI double staining flow cytometry , Western blot and real-time PCR were used to detect cell proliferation , cell migration , cell apoptosis , the levels of AKT , p-AKT, P38MAPK and p-P38MAPK proteinexpressionandtherelativeexpressionofAKTmRNAandP38MAPKmRNA.Results 1)Thecellpolifera-tion decreased in a concentration-dependent manner by Conbercept and Ranibizumab treatment .The optimal con-centration and effect time of Conbercept and Ranibizumab were determined as 225 μg/mL and 24 h.2)Cell prolif-eration and cell migration were significantly decreased in Conbercept group and Ranibizumab group , but meaning-fully increased in VEGF group .Compared with VEGF group , Conbercept+VEGF group and Ranibizumab +VEGF group decreased .3 ) Cell apoptosis decreased in VEGF group , but increased in Conbercept and Ranibizumab group.Compared with VEGF group, cell apoptosis increased in Conbercept and Ranibizumab+VEGF group. 4)There was no differences in the expression of AKT and P38MAPK among groups.The expression of p-AKT, p-P38MAPK, AKT mRNA and P38MAPK mRNA were down-regulated in Conbercept and Ranibizumab group , while up-regulated in VEGF group.The expression of p-AKT, p-P38MAPK, AKT mRNA and P38MAPK mRNA were down-regulated in Conbercept and Ranibizumab +VEGF group .Conclusions Conbercept and Ranibizumab inhibit cell proliferation , migration and related protein expression , but accelerate cell apoptotis .Nevertheless , there is no statistical significance between the impacts of Conbercept and Ranibizumab on the cells .